Head-To-Head Survey: Nektar Therapeutics (NASDAQ:NKTR) and Xenetic Biosciences (NASDAQ:XBIO)

Nektar Therapeutics (NASDAQ:NKTR) and Xenetic Biosciences (NASDAQ:XBIO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Insider and Institutional Ownership

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 7.6% of Xenetic Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Nektar Therapeutics and Xenetic Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-287.84%	-37.87%	-25.67%
Xenetic Biosciences	-75.90%	-40.62%	-34.97%

Analyst Ratings

This is a summary of recent ratings and recommmendations for Nektar Therapeutics and Xenetic Biosciences, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1	2	9	1	2.77
Xenetic Biosciences	1	0	0	0	1.00

Nektar Therapeutics currently has a consensus price target of $138.50, indicating a potential upside of 133.24%. Given Nektar Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Nektar Therapeutics is more favorable than Xenetic Biosciences.

Risk and Volatility

Nektar Therapeutics has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.23, suggesting that its share price is 123% more volatile than the S&P 500.

Earnings and Valuation

This table compares Nektar Therapeutics and Xenetic Biosciences”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$54.59 million	37.14	-$164.08 million	($6.70)	-8.86
Xenetic Biosciences	$2.98 million	1.90	-$2.68 million	($1.16)	-2.13

Xenetic Biosciences has lower revenue, but higher earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Xenetic Biosciences, indicating that it is currently the more affordable of the two stocks.

Summary

Nektar Therapeutics beats Xenetic Biosciences on 9 of the 15 factors compared between the two stocks.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

About Xenetic Biosciences

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.